Daiichi Sankyo Co., Ltd./ US23381D1028 /
2024-05-15 9:59:41 PM | Chg. +0.5100 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
35.1900USD | +1.47% | 200,937 Turnover: 6.64 mill. |
-Bid Size: - | -Ask Size: - | 36.3200 | 34.9800 |
GlobeNewswire
05-01
Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Su...
GlobeNewswire
04-29
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
03-29
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
GlobeNewswire
03-22
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose ...
GlobeNewswire
02-15
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
01-03
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including...
GlobeNewswire
2023-11-29
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breas...
GlobeNewswire
2023-11-28
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
GlobeNewswire
2023-11-02
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire
2023-10-02
Prevent Cancer Foundation raises more than $2 million for cancer prevention and early detection at a...
GlobeNewswire
2023-09-27
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal includ...
GlobeNewswire
2023-09-13
Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Developm...
GlobeNewswire
2023-08-31
RAIN Investors: Contact Robbins LLP for Information Regarding the Pending Lead Plaintiff Deadline in...
GlobeNewswire
2022-03-24
Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform
GlobeNewswire
2022-03-07
Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise